TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

GVOKE PFS

GLUCAGON
Approved 2019-09-10
Jump to: Indications Approvals Trials Competitors Safety Patents
2
Indications
--
Phase 3 Trials
6
Years on Market

Details

Status
Discontinued
First Approved
2019-09-10
Routes
SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

XERIS
Active Ingredient: GLUCAGON

GVOKE PFS Approval History

Loading approval history...

What GVOKE PFS Treats

2 FDA approvals

Originally approved for its first indication in 2019 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GVOKE PFS FDA Label Details

Pro

GVOKE PFS Patents & Exclusivity

Latest Patent: Apr 2036

Patents (18 active)

US9649364 Expires Apr 22, 2036
US11590205 Expires Apr 22, 2036
+ 8 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA212097 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.